Schedule dependency of a cadmium-complexing dithiocarbamate analog in mice.
A number of dosing regimens was assessed to determine the optimum schedule of administration of N-(4-methoxybenzyl)-N-dithiocarboxy-D-glucamine (MeOBDCG) in depleting whole-body, renal and hepatic levels of metallothionein-bound cadmium (Cd) in mice. A comparison of 4.0 mmol/kg given as a single injection versus 0.5 mmol/kg given as 8 hourly injections revealed the latter regimen to be superior in reducing renal Cd levels, but less effective than a bolus dose in lowering hepatic Cd concentrations. Administration of 1.33 mmol/kg for 3 consecutive days or 0.8 mmol/kg for 5 days effected a more extensive depletion of renal Cd concentrations than did a single injection of 4.0 mmol/kg. Three injections of 1.0 mmol/kg given at 4- to 7-day intervals were generally more effective in reducing renal Cd concentrations than were 3 consecutive daily injections in mice which had low or moderately high total Cd burdens. The lowest effective dose of MeOBDCG in lowering whole-body, liver and kidney Cd levels when given repetitively was about 0.2 mmol/kg. While schedule variations did not alter appreciably the whole-body Cd reductions at any given total dose of MeOBDCG, repetitive dosing schedules in which injections were given at intervals of several days rather than daily were typically more effective in reducing renal Cd levels. Based upon consideration of pharmacological response as influenced by body surface area, it was calculated that doses of MeOBDCG of the order of 2.0 g/d may be effective in reducing renal Cd levels in individuals with chronic renal dysfunction secondary to chronic Cd intoxication.
Gale
G R
GR
Veterans Administration Medical Center, Charleston, SC 29403.
Smith
A B
AB
Atkins
L M
LM
Singh
P K
PK
Jones
M M
MM
D000818:Animals; D002104:Cadmium / Q000032:analysis / Q000037:antagonists & inhibitors*; D004334:Drug Administration Schedule; D007668:Kidney / Q000032:analysis; D008099:Liver / Q000032:analysis; D008297:Male; D051379:Mice; D013012:Sorbitol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013859:Thiocarbamates / Q000008:administration & dosage*
D013859:Thiocarbamates; D002104:Cadmium; C060427:N-(4-methoxybenzyl)glucamine dithiocarbamate; D013012:Sorbitol